TY - JOUR
T1 - Hormone Receptor Expression and Activity for Different Tumour Locations in Patients with Advanced and Recurrent Endometrial Carcinoma
AU - Luijten, Maartje M.W.
AU - van Weelden, Willem Jan
AU - Lalisang, Roy I.
AU - Bulten, Johan
AU - Lindemann, Kristina
AU - van Beekhuizen, Heleen J.
AU - Trum, Hans
AU - Boll, Dorry
AU - Werner, Henrica M.J.
AU - van Lonkhuijzen, Luc R.C.W.
AU - Yigit, Refika
AU - Krakstad, Camilla
AU - Witteveen, Petronella O.
AU - Galaal, Khadra
AU - van Ginkel, Alexandra A.
AU - Bignotti, Eliana
AU - Weinberger, Vit
AU - Sweegers, Sanne
AU - Eriksson, Ane Gerda Z.
AU - Keizer, Diederick M.
AU - van de Stolpe, Anja
AU - Romano, Andrea
AU - Pijnenborg, Johanna M.A.
N1 - Publisher Copyright: © 2024 by the authors.
PY - 2024/6
Y1 - 2024/6
N2 - Background: Response to hormonal therapy in advanced and recurrent endometrial cancer (EC) can be predicted by oestrogen and progesterone receptor immunohistochemical (ER/PR-IHC) expression, with response rates of 60% in PR-IHC > 50% cases. ER/PR-IHC can vary by tumour location and is frequently lost with tumour progression. Therefore, we explored the relationship between ER/PR-IHC expression and tumour location in EC. Methods: Pre-treatment tumour biopsies from 6 different sites of 80 cases treated with hormonal therapy were analysed for ER/PR-IHC expression and classified into categories 0–10%, 10–50%, and >50%. The ER pathway activity score (ERPAS) was determined based on mRNA levels of ER-related target genes, reflecting the actual activity of the ER receptor. Results: There was a trend towards lower PR-IHC (33% had PR > 50%) and ERPAS (27% had ERPAS > 15) in lymphogenic metastases compared to other locations (p = 0.074). Hematogenous and intra-abdominal metastases appeared to have high ER/PR-IHC and ERPAS (85% and 89% ER-IHC > 50%; 64% and 78% PR-IHC > 50%; 60% and 71% ERPAS > 15, not significant). Tumour grade and previous radiotherapy did not affect ER/PR-IHC or ERPAS. Conclusions: A trend towards lower PR-IHC and ERPAS was observed in lymphogenic sites. Verification in larger cohorts is needed to confirm these findings, which may have implications for the use of hormonal therapy in the future.
AB - Background: Response to hormonal therapy in advanced and recurrent endometrial cancer (EC) can be predicted by oestrogen and progesterone receptor immunohistochemical (ER/PR-IHC) expression, with response rates of 60% in PR-IHC > 50% cases. ER/PR-IHC can vary by tumour location and is frequently lost with tumour progression. Therefore, we explored the relationship between ER/PR-IHC expression and tumour location in EC. Methods: Pre-treatment tumour biopsies from 6 different sites of 80 cases treated with hormonal therapy were analysed for ER/PR-IHC expression and classified into categories 0–10%, 10–50%, and >50%. The ER pathway activity score (ERPAS) was determined based on mRNA levels of ER-related target genes, reflecting the actual activity of the ER receptor. Results: There was a trend towards lower PR-IHC (33% had PR > 50%) and ERPAS (27% had ERPAS > 15) in lymphogenic metastases compared to other locations (p = 0.074). Hematogenous and intra-abdominal metastases appeared to have high ER/PR-IHC and ERPAS (85% and 89% ER-IHC > 50%; 64% and 78% PR-IHC > 50%; 60% and 71% ERPAS > 15, not significant). Tumour grade and previous radiotherapy did not affect ER/PR-IHC or ERPAS. Conclusions: A trend towards lower PR-IHC and ERPAS was observed in lymphogenic sites. Verification in larger cohorts is needed to confirm these findings, which may have implications for the use of hormonal therapy in the future.
UR - http://www.scopus.com/inward/record.url?scp=85195786494&partnerID=8YFLogxK
U2 - 10.3390/cancers16112084
DO - 10.3390/cancers16112084
M3 - Article
C2 - 38893205
AN - SCOPUS:85195786494
SN - 2072-6694
VL - 16
JO - Cancers
JF - Cancers
IS - 11
M1 - 2084
ER -
